Larimar Therapeutics Reports First Quarter 2025 Financial Results

BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2025 operating and financial results.

Completed Dosing of Adolescents in Pharmacokinetic (PK) Run-In Study.

Potential for Accelerated Approval Pathway Based on Skin FXN Concentrations. 

Planned Upcoming Regulatory Discussions. 

50 mg OLE Data Expected in September 2025. 

Planned Transition to Lyophilized Form of Nomlabofusp. 

BLA Submission and Initiation of Global Phase 3 Study on Track

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits